IP Library Patent Application 11416460
Patent Application
App. No. 11/416,460

Focused libraries of genetic packages

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/416,460
Abstract

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

Claims (173)

1 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of:

(1) <1> 1 Y 2 <1> 3 M 4 <1> 5 , wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2) (S/T) 1 (S/G/X) 2 (S/G/X) 3 Y 4 Y 5 W 6 (S/G/X) 7 . wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025, G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3) V 1 S 2 G 3 G 4 S 5 I 6 S 7 <<1> 8 <1> 9 <1> 10 Y 11 Y 12 W 13 <1> 14 , wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H,. I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

2 . The focused library according to claim 1 , wherein HC CDR1s (1), (2) and (3) are present in the library in the ratio 0.80:0.17:0.02.

3 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody facility, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of:

(1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1><1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N;

(3) <1>I<4><1><1>G<5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and

(5) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

4 . The focused library according to claim 3 wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the library in a ratio of 0.54:0.43:0.03.

5 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of:

(1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G;

(8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P,. Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

(9) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

6 . The focused library according to claim 5 , wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

7 . The focused library according to claim 5 or 6 , wherein HC CDR3s (1) through (8) are present in the library in the following proportions:

(1) 0.10

(2) 0.14

(3) 0.25

(4) 0.13

(5) 0.13

(6) 0.11

(7) 0.04 and

(8) 0.10

8 . The focused library according to claim 5 or 6 , wherein the HC CDR3s (1) through (8) are present in the library in the following proportions:

(1) 0.02

(2) 0.14

(3) 0.25

(4) 0.14

(5) 0.14

(6) 0.12

(7) 0.08 and

(8) 0.11

9 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encodes a kappa light chain CDR1 selected from the group consisting of:

(1) RASQ<1>V<2><2><3>LA

(2) RASQ<1>V<2><2><2><3>LA;

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

10 . The focused library of claim 9 , wherein CDR1s (1) and (2) are present in the library in a ratio of 0.68:0.32.

11 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR2 having the sequence:

<1>AS<2>R<4><1>,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY.

12 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of:

(1) QQ<3><1><1><1>P<1>T,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P, wherein 1 and 3 are as defined in (1) above;

(3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

13 . The focused library according to claim 12 , wherein CDR3s (1), (2) and (3) are present in the library in a ratio of 0.65:0.1:0.25.

14 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS,

wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW;

(2) G<2><4>L<4><4><4><3><4><4>, wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

15 . The focused library according to claim 14 , where CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

16 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR2 has the sequence:

<4><4><4><2>RPS,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

17 . A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

(2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

18 . The focused library according to claim 17 , wherein CDR3s (1) and (2) are present in the library in an equimolar mixture.

19 . The focused library according to claim 1 or 2 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of:

(1) one or more of the heavy chain CDR2s defined in claim 3 or 4 ;

(2) one or more of the heavy chain CDR3s defined in claims 5 , 6 , 7 , or 8; and

(3) mixtures of vectors or genetic packages characterized by (1) and (2).

20 . The focused library according to claim 3 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 5 , 6 , 7 or 8 .

21 . The focused library according to claim 19 or 20 , further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of

(1) one or more the kappa light chain CDR1s defined in claim 9 or 10 ;

(2) the kappa light chain CDR2 defined in claim 11;

(3) one or more of the kappa light chain CDR3s defined in claim 12 or 13 ;

(4) one or more of the kappa light chain CDR1s defined in claim 14 or 15 ;

(5) the lambda light chain CDR2 defined in claim 16;

(6) one or more of the lambda light chain CDR3s defined in claim 17 or 18 ; and

(7) mixtures of vectors and genetic packages characterized by one or more of (1) through (6).

22 . A population of variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of:

(1) <1> 1 Y 2 <1> 3 M 4 <1> 5 , wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2) (S/T) 1 (S/G/X) 2 (S/G/X) 3 Y 4 Y 5 W 6 (S/G/X) 7 wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3) V 1 S 2 G 3 G 4 S 5 I 6 S 7 <1> 8 <1> 9 <1> 10 Y 11 Y 12 W 13 <1> 14 , wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M,. N, P, Q, R, S, T, V, W, and Y; and

(4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

23 . The population of variegated DNA sequences according to claim 22 , wherein HC CDR1s (1), (2) and (3) are present in the population in the ratio 0.80:0.17:0.02.

24 . A population of variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of:

(1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1><1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N;

(3) <1>I<4><1><1>G<5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P,. Q, R, S, T, V, W and Y; and <4>and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and

(5) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

25 . The population of variegated DNA sequences according to claim 24 , wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the population in a ratio of 0.54:0.43:0.03.

26 . A population of variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of:

(1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G;

(8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

(9) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

27 . The population of variegated DNA according to claim 26 , wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

28 . The population of variegated DNA sequences according to claim 26 or 27 , wherein HC CDR3s (1) through (8) are present in the population in the following proportions:

(1) 0.10

(2) 0.14

(3) 0.25

(4) 0.13

(5) 0.13

(6) 0.11

(7) 0.04 and

(8) 0.10

29 . The population of variegated DNA sequences according to claim 26 or 27 , wherein the HC CDR3s (1) through (8) are present in the population in the following proportions:

(1) 0.02

(2) 0.14

(3) 0.25

(4) 0.14

(5) 0.14

(6) 0.12

(7) 0.08 and

(8) 0.11

30 . A population of variegated DNA sequences that encode a kappa light chain CDR1 selected from the group consisting of:

(1) RASQ<1>V<2><2><3>LA

(2) RASQ<1>V<2><2><2><3>LA;

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and

(3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

31 . The population of variegated DNA sequences of claim 30 , wherein CDR1s (1) and (2) are present in the population in a ratio of 0.68:0.32.

32 . A population of variegated DNA sequences that encode a kappa light chain CDR2 having the sequence:

<1>AS<2>R<4><1>,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY.

33 . A population of variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of:

(1) QQ<3><1><1><1>P<1>T,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P, wherein 1 and 3 are as defined in (1) above;

(3) QQ3211PPlT, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

34 . The population of variegated DNA sequences according to claim 33 , wherein CDR3s (1) , (2) and (3) are present in the population in a ratio of 0.65:0.1:0.25.

35 . A population of variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS,

wherein <1> is 0.27 T, 0.2.7 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW;

(2) G<2><4>L<4><4><4><3><4><4>,

wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and

(3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

36 . The population of variegated DNA sequences according to claim 35 , where CDR1s (1) and (2) are present in the population in a ratio of 0.67:0.33.

37 . A population of variegated DNA sequences that encode a lambda light chain CDR2 has the sequence:

<4><4><4><2>RPS,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

38 . A population of variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

(2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and

(3) mixtures of variegated. DNA sequence characterized by any of the above DNA sequences.

39 . The population of variegated DNA sequences according to claim 38 , wherein CDR3s (1) and (2) are present in the population in an equimolar mixture.

40 . The population of variegated DNA sequences according to claim 22 or 23 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of:

(1) one or more of the heavy chain CDR2s defined in claim 24 or 25 ;

(2) one or more of the heavy chain CDR3s defined in claims 26 , 27 , 28 or 29 ; and

(3) mixtures of variegated DNA sequence characterized by (1) and (2).

41 . The population of variegated DNA sequences according to claim 24 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 26 , 27 , 28 or 29 .

42 . The population of variegated DNA sequences according to claim 40 or 41 further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of (1) one or more the kappa light chain CDR1s defined in claim 30 or 31 ;

(2) the kappa light chain CDR2 defined in claim 32;

(3) one or more of the kappa light chain CDR3s defined in claim 33 or 34 ;

(4) one or more of the kappa light chain CDR1s defined in claim 35 or 36 ;

(5) the lambda light chain CDR2 defined in claim 37;

(6) one or more of the lambda light chain CDR3s defined in claim 38 or 39 ; and

(7) mixtures of variegated DNA sequences characterized by one or more of (1) through (6).

43 . A population of vectors comprising the variegated DNA sequences of any one of claims 22 - 42 .

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2015
From: LFRP INVESTORS, L.P.
To: DYAX CORP.
Reel/Frame 036902/0703 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2012
From: HEALTHCARE ROYALTY PARTNERS, L.P. F/K/A COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
To: DYAX CORP., A DELAWARE CORPORATION
Reel/Frame 028827/0906 →
SECURITY AGREEMENT Recorded Aug 22, 2012
From: DYAX CORP., A DELAWARE CORPORATION
To: LFRP INVESTORS, L.P., A DELAWARE LIMITED PARTNERSHIP
Reel/Frame 028828/0517 →
SECURITY AGREEMENT Recorded Mar 18, 2009
From: DYAX CORP., A DELAWARE CORPORATION
To: COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
Reel/Frame 022408/0768 →
SECURITY AGREEMENT Recorded Aug 8, 2008
From: DYAX CORP., A DELAWARE CORPORATION
To: COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
Reel/Frame 021354/0324 →
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2008
From: PAUL ROYALTY FUND HOLDINGS II
To: DYAX CORP., A DELAWARE CORPORATION
Reel/Frame 021355/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2007
From: LADNER, ROBERT C.
To: DYAX CORP.
Reel/Frame 020202/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2007
From: LADNER, ROBERT CHARLES
To: DYAX CORP.
Reel/Frame 019499/0553 →
SECURITY AGREEMENT Recorded Aug 24, 2006
From: DYAX CORP.
To: PAUL ROYALTY FUND HOLDINGS II
Reel/Frame 018160/0726 →